[go: up one dir, main page]

FR2663543A1 - HYBRID SWEET PETIRON LYOPHILISATE AND MEDICINES CONTAINING THE SAME. - Google Patents

HYBRID SWEET PETIRON LYOPHILISATE AND MEDICINES CONTAINING THE SAME. Download PDF

Info

Publication number
FR2663543A1
FR2663543A1 FR9007837A FR9007837A FR2663543A1 FR 2663543 A1 FR2663543 A1 FR 2663543A1 FR 9007837 A FR9007837 A FR 9007837A FR 9007837 A FR9007837 A FR 9007837A FR 2663543 A1 FR2663543 A1 FR 2663543A1
Authority
FR
France
Prior art keywords
lyophilisate
content
active principle
total
petiron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR9007837A
Other languages
French (fr)
Other versions
FR2663543B1 (en
Inventor
Rougereau Andre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9007837A priority Critical patent/FR2663543B1/en
Application filed by Individual filed Critical Individual
Priority to KR1019920700366A priority patent/KR920702227A/en
Priority to EP91912699A priority patent/EP0489144A1/en
Priority to CA002065032A priority patent/CA2065032A1/en
Priority to PCT/FR1991/000486 priority patent/WO1992000085A1/en
Priority to JP3511660A priority patent/JPH05500823A/en
Priority to IL98571A priority patent/IL98571A0/en
Priority to ZA914782A priority patent/ZA914782B/en
Priority to IE215591A priority patent/IE912155A1/en
Publication of FR2663543A1 publication Critical patent/FR2663543A1/en
Application granted granted Critical
Publication of FR2663543B1 publication Critical patent/FR2663543B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/42Cucurbitaceae (Cucumber family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50Methods involving additional extraction steps
    • A61K2236/51Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The novel freeze-dried total extract of hybrid mild pumpkin has a homogeneous powdery appearance, a permanent yellow-organe colour, a pH between 6.44 and 6.47, a carbohydrate content of 63-67 %, a lipid content of 6 % +/- 0.5 %, a protein content of 10 % +/- 1 %, and a total carotenoid content of 25 mg +/- 10 % per gramme of the freeze-dried extract. This substance has therapeutical applications, particularly as an orally or transcutaneously administered drug having an anti-inflammatory, antipyretic and pain-killing activity at least as great as that of betamethasone.

Description

Les Cucurbitacées constituent une famille de plantes dicotylédones annuelles répandues dans tous les pays du monde dont les fruits comestibles tels que courges, citrouilles, potirons (cucurbita), melons, concombres (cucumis), pastèques (citrullus), calebasses (Lagenaria) sont largement consommés. Cucurbits are a family of annual broadleaf plants widespread in all countries of the world whose edible fruits such as squash, pumpkins, pumpkins (cucurbita), melons, cucumbers (cucumis), watermelons (citrullus), gourds (Lagenaria) are widely consumed .

Depuis la plus haute Antiquité, ces plantes sont connues pour leurs vertus thérapeutiques bénéfiques et certaines variétés non comestibles, la Bryone (Bryonia), le concombre d'âne (Echallium) pour leur toxicité. Since ancient times, these plants have been known for their beneficial therapeutic properties and certain inedible varieties, Bryone (Bryonia), donkey cucumber (Echallium) for their toxicity.

Elles ont donné lieu à de multiples recherches botaniques, pharmacochimiques, pharmacodynamiques et à des applications thérapeutiques diverses ainsi qu'à de très nombreuses publications et demandes de brevets. They have given rise to numerous botanical, pharmacochemical, pharmacodynamic research and various therapeutic applications as well as to numerous publications and patent applications.

Ces recherches se sont heurtées à la complexité chimique de ces plantes et en conséquence à l'instabilité des résultats recueillis, en raison de la variété infinie des différentes espèces étudiées, non seulement, l'une par rapport à l'autre, mais encore dans chaque espèce à la variation des sources, des saisons, des années, des terrains ensemencés, des façons culturales. This research came up against the chemical complexity of these plants and consequently the instability of the results collected, due to the infinite variety of the different species studied, not only in relation to each other, but also in each species with the variation of the sources, the seasons, the years, the sown grounds, the cultural ways.

La présente invention est relative à un nouveau lyophilisat d'extrait total de potiron doux hybride. The present invention relates to a new lyophilisate of total extract of hybrid sweet pumpkin.

Ce lyophilisat est obtenu à partir d'une variété sélectionnée depuis 12 ans par hybridations successives. La plante est élevée sous contrat de culture biologique. Les contrôles sont effectués périodiquement au niveau du terrain et des eaux de ruissellement au cours et en fin de production. Ce potiron cueilli à maturité, lavé, broyé avec écorce, pulpe et pépins est lyophilisé selon un procédé classique, puis rendu bactériologiquement stable par irradiation au rayonnement gamma. This lyophilisate is obtained from a variety selected for 12 years by successive hybridizations. The plant is raised under organic cultivation contract. The controls are carried out periodically at the level of the ground and runoff during and at the end of production. This pumpkin picked at maturity, washed, ground with bark, pulp and seeds is lyophilized according to a conventional process, then made bacteriologically stable by irradiation with gamma radiation.

La stabilité génétique obtenue par une culture étroitement contrôlée sur une longue période, facilite la standardisation des constantes physico-chimiques du lyophilisat ainsi obtenu.  The genetic stability obtained by a tightly controlled culture over a long period facilitates the standardization of the physico-chemical constants of the lyophilisate thus obtained.

Celui-ci présente les caractéristiques suivantes
Caractères Triacroscopiques et organoleptiques
Poudre fine, homogène et couleur jaune-orange indélébile.
This has the following characteristics
Triacroscopic and organoleptic characters
Fine, homogeneous powder and indelible yellow-orange color.

Odeur herbacée, goût farineux. Herbal odor, farinaceous taste.

Caractères microscopiqlles
L'examen au microscope optique d'une préparation de lyophilisat dans une goutte d'eau distillée selon la Fig. 1 décèle la présence de fibres et l'absence de grains d'amidon allongés.
Microscopic characters
Examination under an optical microscope of a lyophilisate preparation in a drop of distilled water according to FIG. 1 detects the presence of fibers and the absence of elongated starch grains.

Caractères hactériologiques
- quantité de germes aérobies mesophiles
inférieure ou égale à 5,0. 102.
Heteriological characters
- quantity of aerobic mesophilic germs
less than or equal to 5.0. 102.

- quantité de levures et moisissures inférieure ou
égale à 5,0. 102.
- less amount of yeast and mold or
equal to 5.0. 102.

- absence de germes pathogènes, à savoir absence
- d'Escherichia Coli
- de Staphylococcus aureus
- de Pseudomonas aeruginosa
- de Salmonella typhimurium
Caractères physico-chimiques
- pH compris entre 6,44 et 6,47
- métaux lourds < 2ppm
- teneur en glucides comprise entre 63 et 67 %
- teneur en lipides de 6% + 0,5
- teneur en protéines de 10% * 1%
- teneur en carotenoïdes totaux de 25mg * 10% par
gramme de lyophilisat.
- absence of pathogenic germs, namely absence
- of Escherichia Coli
- Staphylococcus aureus
- of Pseudomonas aeruginosa
- of Salmonella typhimurium
Physico-chemical characters
- pH between 6.44 and 6.47
- heavy metals <2ppm
- carbohydrate content between 63 and 67%
- lipid content of 6% + 0.5
- protein content of 10% * 1%
- total carotenoid content of 25mg * 10% per
gram of lyophilisate.

Le dosage est réalisé par spectrophotométrie en ultraviolet à l'aide d'un appareil Perkin-Elmer , par comparaison avec un lot témoin de ss carotène, référence Merck 2236 selon les figures 2 et 3. The assay is carried out by ultraviolet spectrophotometry using a Perkin-Elmer device, by comparison with a control batch of ss carotene, reference Merck 2236 according to FIGS. 2 and 3.

Le produit est insoluble dans l'eau, peu soluble dans l'éthanol et le méthanol, modérément soluble dans l'éther et les huiles, soluble dans le chloroforme.  The product is insoluble in water, sparingly soluble in ethanol and methanol, sparingly soluble in ether and oils, soluble in chloroform.

La conservation de ces paramètres est liée au stockage du produit à l'abri des phénomènes de photosynthèse ou d'oxydation dus à la chaleur. The conservation of these parameters is linked to the storage of the product away from photosynthesis or oxidation due to heat.

L'étudie phermacocinétique du lyophilisat révèle que la richesse en provitamines A (ss carotène) et en lipides de ce lyophilisat est trois fois plus importante que les teneurs correspondantes du potiron courant ou de la carotte; par sa forte concentration en caroténoïdes, le composé induit la bio-synthèse du Retinol et favorise une régénération cellulaire rapide accélérant le processus de cicatrisation par stimulation de la mitose cellulaire. L'huile de pépins en incorporant plus de lipides et plus d'acides gras insaturés, linoléiques et linoléniques, à celui-ci est elle-même un facteur important du pouvoir de pénétration des préparations topiques à usage dermatologique et cosmétique réalisés avec le composé.La demi-vie du lyophilisat a été déterminée dans la mesure de quatre à cinq heures pour une dose thérapeutique de 100 mg/kilo/jour. The phermokinetic study of the lyophilisate reveals that the richness in provitamins A (ss carotene) and in lipids of this lyophilisate is three times greater than the corresponding contents of the current pumpkin or of the carrot; by its high concentration of carotenoids, the compound induces the bio-synthesis of Retinol and promotes rapid cell regeneration accelerating the healing process by stimulation of cell mitosis. The seed oil by incorporating more lipids and more unsaturated fatty acids, linoleic and linolenic, to it is itself an important factor of the penetrating power of topical preparations for dermatological and cosmetic use made with the compound. The half-life of the lyophilisate has been determined to the extent of four to five hours for a therapeutic dose of 100 mg / kg / day.

t'étude towicologique de ce composé a montré
- une très faible toxicité aiguë, la DL 50 déterminée per os chez la souris et le rat étant supérieure à 5 g par kilo;
- une parfaite tolérance après six mois d'administration répétée chez le rat des deux sexes, objectivée par les examens pondéraux, hématologiques, bio-chimiques et anatomo-pathologiques.
the towological study of this compound has shown
- very low acute toxicity, the LD 50 determined per os in mice and rats being greater than 5 g per kilo;
- perfect tolerance after six months of repeated administration in rats of both sexes, demonstrated by weight, hematological, bio-chemical and anatomo-pathological examinations.

L'étude Dharmacoloiaue l'activité anti-inflammatoire a été mise en évidence tant per os que par voie topique selon les méthodes de
- l'oedème à la carragénine
- l'oedème au kaolin.
The Dharmacoloiaue study of anti-inflammatory activity was demonstrated both per os and topically according to the methods of
- carrageenan edema
- edema with kaolin.

L'examen des résultats donnés figure 4 montre que le lypohilisat de potiron administré tant en poudre par la voie orale qu'en gel par la voie cutanée possède une activité anti-inflammatoire hautement significative la première heure et importante les deuxième et troisième heures après chaque prise. Examination of the results given in FIG. 4 shows that the pumpkin lypohilisate administered both in powder form by the oral route and in gel by the cutaneous route has a highly significant anti-inflammatory activity the first hour and significant the second and third hours after each taken.

Dans les mêmes conditions expérimentales, l'action de la betamethasone s'est montrée significative à la première heure, non significative à la deuxième heure, nulle à la troisième.Under the same experimental conditions, the action of betamethasone was shown to be significant at the first hour, not significant at the second hour, zero at the third.

L'activité analgésique a été recherchée et objectivée chez le rat selon la technique de La Belle et Tislow. Les résultats consignés dans la figure 5 montrent que le lyophilisat testé comparativement à la betaméthasone possède une activité égale, voire supérieure à celle-ci. The analgesic activity was sought and objectified in rats according to the technique of La Belle and Tislow. The results recorded in FIG. 5 show that the lyophilisate tested compared to betamethasone has an activity equal to, or even greater than, this.

Les exemples d'applications thérapeutiques indiqués ci-après illustrent plus en détail l'invention sans en limiter la portée, le produit pouvant être prescrit et utilisé seul ou en association avec d'autres principes actifs. The examples of therapeutic applications indicated below illustrate the invention in more detail without limiting its scope, the product can be prescribed and used alone or in combination with other active ingredients.

EXEMPT.E 1
Préparation orale sous forme de granulé micro-encapsulé permettant grâce à un support la libération en moins d'une heure d'une demi-dose d'1,5 g de principe actif et cinq heures après d'une deuxième dose d'1,5 g. Administrée selon une posologie de deux prises par jour, une le matin, l'autre le soir, cette forme pharmaceutique absorbée pendant une à deux semaines, réduit totalement les manifestations inflammatoires et douloureuses.
EXEMPT.E 1
Oral preparation in the form of a micro-encapsulated granule allowing, thanks to a support, the release in less than an hour of a half-dose of 1.5 g of active principle and five hours after a second dose of 1, 5 g. Administered in a dosage of two times a day, one in the morning, the other in the evening, this pharmaceutical form absorbed for one to two weeks, completely reduces inflammatory and painful manifestations.

EXEMPTE 2
Préparation topique (gel, crème ou pommade) permettant grâce à un excipient, huileux ou non, convenablement choisi une application toutes les 2 ou 3 heures sur les parties lésées un dosage de principe actif compris entre 2 et 10% procure une disparition rapide de l'inflammation et/ou de la douleur.
EXAMPLE 2
Topical preparation (gel, cream or ointment) allowing, thanks to an excipient, oily or not, suitably chosen an application every 2 or 3 hours on the injured parts a dosage of active ingredient between 2 and 10% provides a rapid disappearance of the inflammation and / or pain.

EXRMPLE 3
Préparation topique du principe actif suspendu à raison de 50 à 60 mg de lyophilisat dans 100 ml de liquide propulsé par un gaz inerte autorisé tel que l'azote, ce type de forme pharmaceutique étant particulièrement indiqué dans le traitement des brûlures et des escarres.
EXRMPLE 3
Topical preparation of the active ingredient suspended in an amount of 50 to 60 mg of lyophilisate in 100 ml of liquid propelled by an authorized inert gas such as nitrogen, this type of pharmaceutical form being particularly indicated in the treatment of burns and bedsores.

Claims (3)

REVENDICATIONS 1. Lyophilisat d'extrait total de potiron doux hybride obtenu à partir d'une variété de cucurbitacée sélectionnée depuis douze ans par hybridations successives. La stabilité génétique obtenue par une culture étroitement contrôlée sur une longue période permet d'obtenir un principe actif présentant les caractéristiques physico-chimiques suivantes 1. Lyophilisate of total hybrid sweet pumpkin extract obtained from a variety of cucurbits selected for twelve years by successive hybridizations. The genetic stability obtained by a tightly controlled culture over a long period makes it possible to obtain an active principle having the following physicochemical characteristics - pH compris entre 6,44 et 6,47 - pH between 6.44 and 6.47 - métaux lourds < 2ppm - heavy metals <2ppm - teneur en glucides comprise entre 63 et 67 % - carbohydrate content between 63 and 67% - teneur en lipides de 6% + 0,5 - lipid content of 6% + 0.5 - teneur en protéines de 10% + 1% - protein content of 10% + 1% - teneur en carotenoïdes totaux de 25mg + 10% par - total carotenoid content of 25mg + 10% per gramme de lyophilisat. gram of lyophilisate. 2. Médicament anti-inflammatoire antalgique et antipyrétique caractérisé en ce qu'il est constitué par un principe actif selon la revendication 1. 2. Antalgic and antipyretic anti-inflammatory drug, characterized in that it consists of an active principle according to claim 1. 3. Compositions pharmaceutiques caractérisées en ce qu'elles contiennent à titre de principe actif un médicament selon la revendication 2, associé à un ou plusieurs excipients et présentées en granulé, billes micro-encapsulées en granulé ou gélules, crème, gel, pommade, spray.  3. Pharmaceutical compositions characterized in that they contain, as active principle, a medicament according to claim 2, associated with one or more excipients and presented in granules, microencapsulated beads in granules or capsules, cream, gel, ointment, spray .
FR9007837A 1990-06-22 1990-06-22 HYBRID SWEET PETIRON LYOPHILISATE AND MEDICINES CONTAINING THE SAME. Expired - Lifetime FR2663543B1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR9007837A FR2663543B1 (en) 1990-06-22 1990-06-22 HYBRID SWEET PETIRON LYOPHILISATE AND MEDICINES CONTAINING THE SAME.
EP91912699A EP0489144A1 (en) 1990-06-22 1991-06-18 Freeze-dried hybrid mild pumpkin and drugs containing same
CA002065032A CA2065032A1 (en) 1990-06-22 1991-06-18 Freeze-dried hybrid mild pumpkin and drugs containing same
PCT/FR1991/000486 WO1992000085A1 (en) 1990-06-22 1991-06-18 Freeze-dried hybrid mild pumpkin and drugs containing same
KR1019920700366A KR920702227A (en) 1990-06-22 1991-06-18 Lyophilized Samples of Hybrid Pumpkin and Drugs Containing the Same
JP3511660A JPH05500823A (en) 1990-06-22 1991-06-18 Freeze-dried hybrid pumpkin with low irritation and medicine containing the same
IL98571A IL98571A0 (en) 1990-06-22 1991-06-20 Lyophilisate of hybrid sweet pumpkin and medicaments containing it
ZA914782A ZA914782B (en) 1990-06-22 1991-06-21 Lyophilisate of hybrid sweet pumpkin and medicaments containing it
IE215591A IE912155A1 (en) 1990-06-22 1991-06-21 Lyophilisate of hybrid sweet pumpkin and medicaments¹containing it

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9007837A FR2663543B1 (en) 1990-06-22 1990-06-22 HYBRID SWEET PETIRON LYOPHILISATE AND MEDICINES CONTAINING THE SAME.

Publications (2)

Publication Number Publication Date
FR2663543A1 true FR2663543A1 (en) 1991-12-27
FR2663543B1 FR2663543B1 (en) 1992-10-16

Family

ID=9397897

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9007837A Expired - Lifetime FR2663543B1 (en) 1990-06-22 1990-06-22 HYBRID SWEET PETIRON LYOPHILISATE AND MEDICINES CONTAINING THE SAME.

Country Status (9)

Country Link
EP (1) EP0489144A1 (en)
JP (1) JPH05500823A (en)
KR (1) KR920702227A (en)
CA (1) CA2065032A1 (en)
FR (1) FR2663543B1 (en)
IE (1) IE912155A1 (en)
IL (1) IL98571A0 (en)
WO (1) WO1992000085A1 (en)
ZA (1) ZA914782B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2760366A1 (en) * 1997-03-04 1998-09-11 Harbex Limited Powdered sweet pumpkin hydrolysate preparation in high yield

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4408330A1 (en) 1994-03-11 1995-09-14 Cherry Mikroschalter Gmbh Ergonomic keyboard
FR2732347A1 (en) * 1995-03-30 1996-10-04 Bio Media Plant extract used as cell growth factor medicament with antitumoural and anticancer activity
PT912191E (en) * 1997-04-16 2003-09-30 Hubert Jean Marie Fr Gillessen METHOD FOR THE PREPARATION OF THIS AND ITS APPLICATIONS IN HUMAN AND VETERINARY MEDICINE
FR2836046B1 (en) * 2002-02-15 2006-09-15 Marie Jose Touche NOVEL THERAPEUTIC APPLICATION OF COMPOUND A: BUTOFORM OR SCUROFORM ASSOCIATED WITH PRODUCT B: EUGENOL AND PRODUCT C: ZINC OXIDE, ADDED TO LYCOPENE
CN107456562A (en) * 2017-08-10 2017-12-12 靖西市民族医药协会 One kind is brought down a fever wine and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL63333C (en) * 1900-01-01
FR2522500A1 (en) * 1982-03-02 1983-09-09 Rougereau Andre Chinese pumpkin or okaido or analogous cucurbitaceae pulp - used as medicament and cosmetic having antiinflammatory, antipyretic, analgesic, antiallergic, keratolytic, skin penetrating etc. activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL63333C (en) * 1900-01-01
FR2522500A1 (en) * 1982-03-02 1983-09-09 Rougereau Andre Chinese pumpkin or okaido or analogous cucurbitaceae pulp - used as medicament and cosmetic having antiinflammatory, antipyretic, analgesic, antiallergic, keratolytic, skin penetrating etc. activity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2760366A1 (en) * 1997-03-04 1998-09-11 Harbex Limited Powdered sweet pumpkin hydrolysate preparation in high yield

Also Published As

Publication number Publication date
EP0489144A1 (en) 1992-06-10
JPH05500823A (en) 1993-02-18
IL98571A0 (en) 1992-07-15
FR2663543B1 (en) 1992-10-16
CA2065032A1 (en) 1991-12-23
ZA914782B (en) 1992-03-25
IE912155A1 (en) 1992-01-01
KR920702227A (en) 1992-09-03
WO1992000085A1 (en) 1992-01-09

Similar Documents

Publication Publication Date Title
EP0022046B1 (en) Drug composition based on plants and process for its preparation
Nwosu Ethnobotanical studies on some pteridophytes of Southern Nigeria
WO2000041708A1 (en) Composition for treating obesity and aesthetic treatment method
CH674617A5 (en)
US8668944B2 (en) Topical oil for treating physical ailments and method for making and applying the same
EP3454875A1 (en) Method for producing celastrol and pentacyclic triterpene derivatives
FR2663543A1 (en) HYBRID SWEET PETIRON LYOPHILISATE AND MEDICINES CONTAINING THE SAME.
US5665360A (en) Method of treating peripheral neuropathies of the feet and legs
Norten Neem: India's miraculous healing plant
WO2021099453A1 (en) Aqueous liquid extract of spirulina for preventing and/or treating peripheral chemotherapy-induced neuropathies and the symptoms thereof, and corresponding composition and use
FR2513122A1 (en) NEW MEDICINES BASED ON ALGAE EXTRACTS AND CORRESPONDING FORMULATIONS
FR2953725A1 (en) PROCESS FOR OBTAINING STANDARDIZED EXTRACT OF QUERCETIN AND 3-O-METHYLQUERCETIN FROM MACELA-DO-CAMPO INFLORESCENCE AND COSMETIC, PHARMACEUTICAL AND VETERINARY COMPOSITION CONTAINING THE SAME
CA2725770C (en) Plant-based compositions and uses
BE1000189A3 (en) Pharmaceutical preparation for animal treatment.
RU2203081C1 (en) Islacet preparation for preventing and treating tuberculosis and method for its embodiment
FR2884828A1 (en) BASIS OF PRODUCTS COMPRISING PLANTS HAVING ST IMULANT PROPERTIES FOR THE NERVOUS SYSTEM AND PSYCHOTROPIC, APHRODISIVE AND DEPURATIVE ENERGETIC ANTIOXIDANT
FR2991181A1 (en) Composition, useful for inhibiting intestinal absorption of sugar and for treating metabolic syndrome and diabetes, and as a medicament or dietetic product against weight gain, comprises an aqueous extract of Boscia senegalensis
FR2878163A1 (en) NOVEL PHARMACEUTICAL COMPOSITIONS WITH A PHYTOTHERAPEUTIC VIEW
RU2722067C2 (en) Herbal medicinal liqueur and method for production thereof
US20070202207A1 (en) Use of naturally occurring epoxidised molecules from Vernonia Galamensis
FR2686019A1 (en) Composition of sap and of plant extract
EP0404660B1 (en) Use of glycoprotein complex extracts of gram (-) bacteria for the preparation of a medicament to facilitate the cicatrisation of the skin and a method for its preparation
FENTOUS et al. Etude phytochimique et valorisation des extraits bruts des feuilles de grenadier d’Ain Témouchent «Punica granatum» par l'étude de son activité antioxydante
WO2022090561A1 (en) Natural composition for gastric treatment, particularly for treating gastric ulcers, associated manufacturing method and administration thereof to equids
OA20988A (en) Phytomedicine based on extracts of two medicinal plants for the treatment of uncomplicated malaria and its preparation process.

Legal Events

Date Code Title Description
TP Transmission of property
ST Notification of lapse